Progress in genomics and the associated technological, statistical and bioinformatics advances have facilitated the successful implementation of genome-wide association studies (GWAS) towards understanding the genetic basis of common diseases. Infectious diseases contribute significantly to the global burden of disease and there is robust epidemiological evidence that host genetic factors are important determinants of the outcome of interactions between host and pathogen. Indeed, infectious diseases have exerted profound selective pressure on human evolution. However, the application of GWAS to infectious diseases has been relatively limited compared with non-communicable diseases. Here we review GWAS findings for important infectious diseases, including malaria, tuberculosis and HIV. We highlight some of the pitfalls recognized more generally for GWAS, as well as issues specific to infection, including the role of the pathogen which also has a genome. We also discuss the challenges encountered when studying African populations which are genetically more ancient and more diverse that other populations and disproportionately bear the main global burden of serious infectious diseases.
INTRODUCTION
The global burden of both death and disability due to infectious diseases is huge; according to World Health Organization statistics almost 12 million people died from infection in 2004 [1] . The majority of these deaths were due to diarrhoea and pneumonia in children under the age of 5 years [2] . HIV/ AIDS, tuberculosis (TB) and malaria feature at positions 4, 7 and 9, respectively, in the top 10 causes of death in low income countries [1] . Meanwhile, the group of neglected tropical infectious diseases which includes lymphatic filariasis, onchocerciasis, trachoma, dracunculiasis (guinea worm) and soil transmitted helminths are responsible for more days lost due to disability or death than malaria or TB [3] . Much of this global burden is linked to the effects of poverty such as poor sanitation, malnutrition and the lack of access to adequate health care and simple treatments such as oral rehydration fluid and antibiotics. Many more childhood deaths could be prevented through vaccination. However, the impact of diseases for which there are no effective vaccines remains high and a number of infections such as TB and malaria are increasingly difficult to treat due to multidrug resistance [4] . There is also increasing concern around the impact of emerging and re-emerging infectious diseases such as pandemic H1N1 influenza. Advances in genetics and genomics that have shown some success in identifying susceptibility loci for non-communicable diseases are being applied to identify key host pathways involved in immunity to infectious diseases with the aim of facilitating the development of much needed new drugs and vaccines.
ROLE OF GENETIC FACTORS IN INFECTIOUS DISEASES
The spectrum of clinical disease following infection with a potentially pathogenic microorganism is highly variable, ranging from asymptomatic carriage or mild illness to rapidly progressive disease and death. Epidemiological studies have highlighted the role of host genetic factors as determinants of this spectrum of clinical phenotypes. For example, twin studies have demonstrated that infectious diseases such as TB, leprosy, malaria and pneumonia have a heritable component to them [5] [6] [7] [8] , paving the way for further studies to identify specific genes involved [9] . Infectious diseases have been a major selective force on human evolution as evidenced by the classical protective effect of the sickle cell polymorphism in the b-globin gene (HBB) against malaria in heterozygous carriers [10] . A point mutation in a transcription factor binding site in the promoter region of the gene encoding the Duffy antigen receptor for chemokines (DARC), which acts as a receptor for Plasmodium vivax, abrogates protein expression on the erythrocyte, leading to resistance to P. vivax malaria [11, 12] . In the case of HIV infection, a 32 base pair deletion in the chemokine receptor 5 (CCR5) gene, exploited by the virus as a co-receptor to gain entry into target cells, prevents expression of the receptor, making cells genetically resistant to HIV infection [13] . Understanding the molecular basis of HIV resistance in CCR5del32 homozygotes led to the development of a new class of anti-retroviral drugs highlighting the potential for genetics as a tool in drug discovery [14] .
There are also numerous examples of mutations in single genes that lead to increased susceptibility to infection. For example, mutations in genes encoding cytokines and receptors in the interleukin-12 (IL-12)/interferon-gamma (IFN-) pathway result in increased susceptibility to infection with intracellular pathogens including Mycobacteria and Salmonella species [15] [16] [17] . However, while such 'experiments of nature' highlight the important biological pathways required for immunity they are rare and most individuals with increased susceptibility to infection at the population level do not have Mendelian defects. Rather, infectious diseases are complex traits resulting from the interaction between host genetic variants, environmental factors and of course a pathogen which has its own genome.
IDENTIFYING INFECTIOUS DISEASE SUSCEPTIBILITY GENES
Approaches used to identify genes in complex common disorders such as diabetes and cancer have been adapted to investigate infectious diseases. Use of genome-wide association studies (GWAS) is the currently favoured approach to identifying variants involved in complex diseases. However, before GWAS became possible, genome-wide linkage methodology that had proved successful for mapping single gene disorders was adapted and applied to complex traits. In particular, affected sibling pair (ASP) methodology was favoured [18] . First, by including only affected individuals there was no room for ascertainment errors in unaffected individuals. This is an important consideration for infectious diseases where it is important to distinguish between an unaffected individual who is genetically resistant and an unaffected individual who is genetically susceptible but unexposed to the pathogen. Secondly, the ASP methodology is non-parametric-i.e. it does not require a model specifying the nature of the relationship between the phenotype and genotype, which is usually unknown for complex diseases. Genome-wide linkage scans were reported for a number of infectious diseases and a number of susceptibility/resistance loci identified e.g. [19] [20] [21] [22] [23] [24] [25] .
The main weakness of ASP studies is the lack of power compared with association studies [26] . The identification of families with multiple cases and available parents is a further limitation for infectious diseases. Thus association studies were favoured. However, before the development of a sufficiently dense genetic map of polymorphisms and the high throughput genotyping facilities required to exploit the map, a high resolution genome-wide approach was not possible. Researchers focused on candidate genes but the majority of studies were underpowered and findings unreproducible [27] . The advent of GWAS, made possible by a combination of the HapMap project which provided a catalogue of human genetic variation (focusing on single nucleotide polymorphisms, SNPs) [28, 29] and advances in genotyping technology, was heralded by the publication of the Wellcome Trust Case Control Consortium (WTCCC) study of seven common non-communicable diseases. This demonstrated the feasibility of such studies on a large scale and led to the identification of several new genes for common diseases [30] . The number of published GWAS is growing rapidly-as of 30 November 2010, the National Human Genome Research Institute had registered 714 GWAS publications on its catalogue [31, 32] , and it is likely this is not exhaustive as inclusion is voluntary [33] . However, the proportion of these that focus on infectious diseases is small (there are currently 19 published GWAS for infectious diseases, representing just six diseases) perhaps reflecting the relatively small burden of disease compared with non-communicable diseases in the resource-rich setting where the majority of GWAS have been conducted. The aims of GWAS in infectious diseases are to identify susceptibility/resistance genes that could be targets for new vaccines and drugs, to identify variants that influence or predict the clinical course of diseases once infection is established and to identify genetic correlates of responses to treatment.
HIV
HIV infection was the first infection for which a GWAS was reported [34] . It is perhaps not surprising that HIV has been studied so widely given its global impact, the lack of an effective vaccine and the need for new anti-retroviral drugs to combat drug resistance. In addition to the CCR5del32 mutation that confers resistance to HIV infection, candidate gene analysis had identified several other HIV susceptibility genes including those encoding class I Human Leukocyte Antigen (HLA) antigens, killer immunoglobulin-like receptor molecules (KIRs), cytokines, cytokine receptors and other chemokine receptors [35] . Genetic factors also influence other aspects of HIV/AIDS such as disease progression after infection (for example, heterozygotes for CCR5del32 are susceptible to infection with HIV but their disease progresses more slowly-so-called long term non-progressors [36] ) and other clinical phenotypes. Genetic factors may also influence response to treatment as illustrated by the role of the HLA antigen B*5701 allele in severe hypersensitivity reactions to an anti-retroviral agent abacavir, which was sometimes fatal [37] .
The GWAS study by Fellay et al. [34] investigated association between SNPs in the Illumina 550 K array, viral load and rate of decline of the CD4 T lymphocyte count in 486 subjects. Two SNPs within the class I HLA region accounted for 15% of the variation in viral load, while a further seven SNPs were associated with time to disease progression. One of the HLA SNPs was located near the HLA-C locus and the other in an endogenous retroviral element (HCP5) which has homology to the HIV pol gene and is in strong linkage disequilibrium (LD) with HLAB*5701, a known HIV1 restriction factor. The genes that were identified as regulators of viral load did not overlap with the genes identified as regulators of disease progression despite the reported correlation between these parameters. These findings were replicated in a different study which attributed the effects of HCP5 and HLA-C to either HLA-A10 or HLA-B*57, reflecting the LD within the HLA region [38] . Fellay et al. [39] extended their original studies to include more than 2500 HIV infected individuals and showed that genetic variants located near the HLA-B and HLA-C genes are the most strongly associated with viral control. The other important finding from this study was that numerous loci identified previously through candidate gene studies were not confirmed. This may reflect previous false positive results, but given GWAS did not identify genes such as CCR5, a known HIV resistance gene, it is possible that this is a consequence of the stringent statistical criteria for association in GWAS which aim to limit the detection of false positive rather than false negative results [40] .
A trio of GWAS conducted under the auspices of the French ANRS (National Agency for AIDS Research) reported associations between genetic variation and (i) control of plasma HIV-RNA/cellular HIV DNA levels in seroconverters (i.e. acute primary infection), (ii) non-progression of disease and iii) rapid progression to AIDS [41] [42] [43] . The first two studies again confirmed the role of the HLA locus on 6p21 and identified novel loci on chromosomes 8 and 17 also associated with plasma HIV RNA/DNA levels. Minor alleles of the top three SNPs in this study (rs 2305029 in the HLA region, rs6503919 an intergenic SNP on chromosome 17 and rs2575735 within the syndecan 2 gene on chromosome 8) were associated with 0.53, À0.62 and À0.37 log10 differences in cellular HIV DNA levels, respectively. The HCP5 variant that was identified by Fellay et al. as a factor in non-progression was confirmed and in a combined meta-analysis of the two data sets {P ¼ 6.79 Â 10 A smaller GWAS investigating clinical progression to AIDS in 156 people with extreme phenotypes (rapid versus non-progression) conducted in the US identified a significant association with a locus on chromosome 1 36 kb upstream of PROX1 with a relative hazard ratio of 0.69 [44] . A GWAS of host determinants of HIV-1 control found a strong association between HLA B*5703 and viral load set point in African Americans, explaining $10% of the variation in viral load setpoint in this cohort and mirroring the role of HLAB*5701 as a determinant of HIV outcome in people of Caucasian origin [45] .
Other aspects of HIV biology and disease have been investigated by GWAS including the role of the X chromosome, the role of the HIV-associated HLA locus in CD4:CD8 T lymphocyte ratios and genetic factors that may influence mother to child transmission. Briefly, following up on data generated through a GWAS in rhesus macaques, an association between SNP rs5968255 on the Xq21.1 region and slow progression to AIDS was reported in human females but not males [46] . The authors estimated that this SNP explained between 21 and 25% of the variance in female log-progression phenotype. HLA variants that are strongly associated with control of HIV viral load are independently associated with the CD4:CD8 ratio which is dysregulated in HIV infection [OR (CI) 0.31 (0.25-0.37)] [47] . A relatively small GWAS comparing 100 HIV infected with 126 uninfected infants all born to HIV infected mothers used a cut-off of P < 5 Â 10 À5 to identify nine SNPs within six genes that were associated with reduced rate of transmission [best OR (CI) 0.27 (0.14-0.51)] [48] .
Viral hepatitis
Hepatitis B and hepatitis C viruses cause chronic liver inflammation that can lead to cirrhosis and hepatocellular carcinoma. There is wide variation in clinical outcomes after infection: for example, $30% of individuals with hepatitis C virus infection clear infection without liver damage but persistent infection and the development of chronic disease is associated with ineffective immune responses and high viral load in others [49] .
Candidate gene studies had shown that the genes encoding IFN-, tumour necrosis factor, the vitamin D receptor, the oestrogen receptor-alpha and several HLA loci associate with chronic hepatitis B virus infection, and HLA, KIR and various chemokine and interleukin genes with the control of hepatitis C virus infection [50] [51] [52] . However, none proved conclusive and the genome-wide association approach was adopted. A GWAS conducted in Japanese and replicated in Thai subjects with chronic hepatitis B infection demonstrated that the HLA-DP locus was strongly associated with risk of persistent infection: a meta-analysis of the combined cohorts showed OR (CI) 0.56 (0.51-0.61) for HLADPA1 and 0.57 (0.52-0.62) for HLADPB1 [53] . Haplotypes HLA-DPA1*0202-DPB1*0501 and HLA-DPA1*0202-DPB1*0301 were associated with increased risk of chronic infection [OR (CI) Studies in hepatitis C have focused on the identification of genetic variants associated with response to treatment. There is treatment available for hepatitis C infection but response to treatment is variable. While it is recognized that viral genotypes determine outcomes of treatment this does not explain all the variation observed. Four GWAS investigating response to treatment have been conducted and have been summarized elsewhere [55, 56] . These studies consistently identified a SNP (rs12979860) located close to the gene that encodes interleukin 28B (IL28B) as a predictor of viral clearance following treatment with ribavirin and pegylated alpha interferon [57] [58] [59] [60] [56, 58] may reflect the variation allele frequencies in the different populations studies (Japanese versus various populations of Caucasian origin) and differences in study design. IL-28B is up regulated by interferons and by infection with RNA viruses and is in linkage disequilibrium with other genes encoding antiviral proteins on chromosome 19. The effect of the polymorphism in IL28B is of similar magnitude in all populations studied including Caucasian, African American, Hispanic and Japanese. However, the allele frequency differs significantly between populations which may explain the much lower rate of spontaneous clearance of hepatitis C virus in people of African origin (9.3% in one study compared with 36.4% in the rest of the study population [61] ) in which the protective allele frequency is approximately half that seen in populations of European origin [56, 61, 62] . This example illustrates the importance of collecting genomic data that are specific to the population under investigation and the need to focus on the disease-related effect of any given genetic variant in individuals rather than relying on generalizations based on population categories [63] .
Malaria
Plasmodium falciparum malaria, a parasitic infection of the red blood cells, is responsible for the death of approximately one million people each year, the majority of whom are children in sub Saharan Africa [1] . Severe malaria has a heritability of 25% in children living in coastal Kenya, though the sickle haemoglobin (HbS) polymorphism in HBB accounts for only 2% of the total genetic variation suggesting there are many other genes involved [64] . Indeed a number of resistance genes have already been identified [65] . The malaria GWAS reported in Nature Genetics in 2007 was the first to be done in African subjects and highlighted some interesting challenges. The initial scan was conducted in 1060 cases and 1500 control samples from The Gambia, west Africa, using the Affymetrix Gene Chip 500 K Mapping Array Set that was used in the WTCCC study. Six SNPs were associated with malaria at P < 10 À6 and the strongest association was found for a SNP close to HBB on chromosome 11p15 [P ¼ 3.9 Â 10 À7 , OR (CI) 0.61 (0.50-0.74)] [66] . This seemed surprisingly weak given the known association with HbS. By comparison, GWAS studies in Caucasian populations easily identified established associations between genetic variants and disease, acting as positive controls for the experiments. For example, certain HLA genes and mutations in CARD15 (caspase recruitment domain family, member 15; also known as NOD2) were already known to predispose to type 1 diabetes [67, 68] and Crohn's disease [69] [70] [71] , respectively. In the WTCCC GWAS, done using the same array, the CARD15 SNP was associated with Crohn's disease at P ¼ 9.4 Â 10 À12 [30] , while the known association between diabetes and HLA was confirmed with a P-value of 2.42 Â 10 À134 [30] .
The authors went on to explore the HBB region in more depth in their study population. When the HbS polymorphism was typed directly in the same samples a much stronger signal of association was found (P ¼ 1.3 Â 10 À28 ). A 111 kb region spanning the original GWAS signal on chromosome 11p15 was sequenced in 62 individuals and the data used to impute genotypes for the whole cohort, which were then tested for association. Imputation uses data from a reference population or sequence to predict the most likely genotypes for SNPs not genotyped directly in a study [72] . Three of the 202 new SNPs identified through sequencing had stronger signals of association when imputed than the original GWAS SNP, the strongest being the HbS SNP at P ¼ 4.5 Â 10 À14 . However, when HapMap data generated in people of Yoruba origin (also from West Africa) were used as a reference to impute HbS genotypes in the Gambian population no association signal was identified (P ¼ 0.06). This work highlights the wider diversity and the lower LD in African populations compared with Caucasian populations, whose data were used to develop the GWAS SNP chips [73] . It is estimated that three times as many SNPs are required to get equivalent resolution for GWAS in African populations [74] . While lower LD will enhance fine mapping studies, this study illustrates the importance of using reference data derived from the population under investigation to understand regional variation and haplotype structure.
The malaria GWAS also investigated other known malaria susceptibility loci including G6PD, HBA1-HBA2 and the ABO locus. None was identified when data from the Affymetrix Chip SNPs were analysed, again due to the limited resolution of the SNPs included in the Chip given the LD structure in the populations under investigation.
Tuberculosis
TB is an infectious disease caused by M. tuberculosis, a slow-growing intracellular bacterium that causes diverse clinical phenotypes ranging from latent (asymptomatic) infection through various manifestations of pulmonary disease to disseminated disease including meningitis. Up to 40% of variation in susceptibility to TB is attributable to genetic factors in some populations yet attempts to identify the genetic variants involved have generally been disappointing [75] . Associations have often not been replicated across populations most likely reflecting under-powered studies and wide phenotypic variation. Data from two GWAS conducted in Gambian and Ghanaian subjects were combined to identify 17 SNPs with P 10 À5 [76] . These SNPs were tested in a different Ghanaian case-control cohort and when combined with the GWAS data, two SNPs remained in the running with association signals of P < 5 Â 10 À7 . Further samples from Ghana and Malawi were used as a second replication set to identify a single SNP in a gene-poor-region of chromosome 18q11 which conferred a rather modest odds ratio of 1.19 (CI ¼ 1.13-1.27 ). This disappointing result may again reflect the poor representation of relevant variants in the GWAS array used (again the Affymetrix Gene Chip 500 K Mapping Array Set for the initial Gambian study and the Affymetrix SNP array 6.0 in the Ghanaian cohort) in the context of low levels of LD in African populations. The findings reinforce the conclusions from the malaria GWAS that genotyping and data analysis tools developed in Caucasian populations are less effective in non-European populations and population-specific data are required [77] .
Leprosy
Leprosy is also a chronic mycobacterial infection that has a predilection for the skin and nerves. Again, there is much epidemiological evidence that susceptibility to diseases is genetically regulated and variants in HLA-DR, NRAMP1 (encoding natural resistance associated macrophage protein 1, now known as SLC11A1) and the genes encoding parkin (PARK2) and lymphotoxin alpha (LTA) have been linked to susceptibility to leprosy [78] . More recently, a genome-wide association study of leprosy was reported in a Chinese population [79] . This study identified a significant association between 15 genetic variants in six genes [CCDC122, best OR (CI) 1.87 (1.38-2.53); C13orf31, best OR (CI) 1.97 (1.49-2.62); NOD2, best OR (CI) 2.28 (1.70-3.06); TNFSF15, best OR (CI) 1.60 (1.22-2.10); HLA-DR, best OR (CI) 0.58 (0.43-0.79); and RIPK2, best OR (CI) 0.66 (0.51-0.87)], three of which map to the NOD2-mediated signalling pathway, an important regulator of the innate immune response. As discussed for HIV and malaria, the leprosy GWAS did not identify genes previously found to be linked to or associated with susceptibility to leprosy, other than HLA loci. Class II HLA loci were identified in both the TB and leprosy GWAS (albeit weakly for TB), but there was otherwise no overlap between the two studies despite the common mycobacterial aetiology.
However, there was significant overlap between the leprosy GWAS findings and those for Crohn's disease, a chronic inflammatory disease of the bowel. There is epidemiological evidence that Crohn's disease may be triggered by infection (on a background of other environmental and genetic factors [80] ) but no specific organisms have been identified. However, Crohn's disease resembles Johne's disease in cattle, which is known to be caused by M. avium subspecies paratuberculosis, fuelling speculation that Crohn's disease is infact due to mycobacterial infection [81] . Previous linkage and association studies identified NOD2 as a susceptibility gene for Crohn's disease [69] [70] [71] . This was replicated in the WTCCC GWAS for Crohn's which also identified leprosy candidate TNFSF15 as a Crohn's susceptibility locus [30, 82] . NOD2 plays an important role as a pathogen associated molecular pattern receptor and triggers innate immune responses via activation the nuclear factor kappa B pathway [83] .
Miscellaneous infections
A genome-wide association study for host susceptibility to meningococcal disease identified associations between variants in the genes encoding complement factor H (CFH) and CFH-related protein 3 [OR (CI) 0.67 (0.59-0.76) and 0.63 (0.55-0.71), respectively] which were biological plausible giving the role of complement activation in severe disease induced by Neisseria meningitidis [84] .
Kawasaki's disease is a paediatric vasculitis that has a predilection for the coronary arteries. It bears the hallmarks of a superantigen-mediated infectious disease yet a causative pathogen has yet to be identified. A recently-reported GWAS in 119 cases and 135 controls with follow-up replication in 893 cases with family and population controls identified significant associations with 40 SNPs in 31 genes [OR (CI) ranging from 0.39 (0.24-0.63) to 3.52 (1.60-7.75)] [85] . Pathway analysis identified five genes which mapped to relevant inflammatory pathways.
SUMMARY AND CONCLUSIONS
The studies described in this review indicate that the GWAS approach has facilitated some progress towards identifying host genetic factors associated with susceptibility to infectious diseases, as well as variation in clinical phenotypes and response to treatment, for a limited number of diseases. Some studies have confirmed roles for genes already known to be associated with particular diseases or clinical phenotypes (e.g. HLA loci and susceptibility to HIV, leprosy and TB and disease progression in HIV) while others have identified new genes and pathways (e.g. genes mapping to the NOD2 pathway in leprosy). Variation in genes from both innate and adaptive arms of the immune system have been implicated, and the first step towards understanding the molecular mechanisms of disease that are potential targets for new treatments and vaccines have been taken. However, with the exception of IL28B and response to treatment in Japanese subjects with hepatitis C infection, the odds ratios reported generally indicate small effects for the majority of genetic variants identified. Improved study designs (for example larger sample sizes and whole genome sequencing approaches) will be required to address this issue and detect effects missed so far with the GWAS approach. Consideration also needs to be given to the role of the environment and the fact that genetic variants may express their effects differently in different environments.
Meanwhile, previously reported associations have not been replicated in GWAS data sets. There is a range of possible explanations for this observation, highlighting the need for rigorous clinical phenotyping (and as studies get even larger and subject recruitment occurs at multiple centres, ensuring phenotype data is consistent and accurate is critical), the need for population specific reference data (as exemplified by the malaria GWAS) and alternative statistical tools that meet the challenges presented by such large and complex data sets. Another limitation of the GWAS approach is that current study designs will only identify common variations and further studies are required to identify the causal variant (which may not be a SNP). As experience with GWAS grows the science will become more refined and/or other techniques aimed at discovering disease-causing variants will be applied-for example direct sequencing.
Finally, there are two genomes involved in infectious diseases and there is much research activity focused on pathogen genetics too. Well over a thousand microbial genomes have now been sequenced (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi), pathogenicity and virulence genes have been identified and new drug targets identified [86, 87] . For example, a GWAS conducted in the malaria parasite P. falciparum identified genes under positive selection from antimalarial drugs that could lead to new drugs for malaria [88] . Pathogen genome sequencing has also aided vaccine development. For example, analysis of the genome sequence of N. meningitidis serogroup B (where vaccine development has been slow compared with the other serogroups due to its poorly immunogenic capsular polysaccharide) led to the identification of 570 genes predicted to encode surface-exposed or secreted proteins. Further screening led to the incorporation of five antigens into a vaccine that is now in clinical trials [89] . Studies are also emerging to suggest that pathogen genotype may correlate with clinical phenotype: in the case of TB, different M. tuberculosis strains were found to be associated with different clinical presentations and outcomes in Vietnamese and Indian populations [90] [91] [92] , although further studies are required to confirm this link.
In the case of infectious diseases, pathology and subsequent morbidity and mortality arise as a result of the host response to the pathogen and further progress towards understanding the molecular mechanisms of infectious diseases will be hampered if studies do not focus more on host-pathogen interactions [93] . At the genome level, studies of infection in plants and insects have shown interaction between host and pathogen genomes through RNA silencing (a form of post transcriptional gene regulation) which has long been recognized as the equivalent of the innate immune system in plants [94, 95] . Phytopathogens in turn have acquired genes that encode molecules that counter the host silencing response [96] . There are also examples of microRNA molecules that interfere with viral transcripts in humans. MicroRNA-122 is expressed in the liver and binds to the 5 0 -untranslated region of the hepatitis C genome, apparently facilitating viral replication [97] . The potential for therapeutic intervention by inhibition of miRNA-122 has been explored in chimpanzees with promising results [98] . Other studies indicating that specific interactions between polymorphic human and pathogen molecules are likely to be important have also been reported. For example, in addition to demonstrating a link between clinical phenotype and M. tuberculosis strain in Vietnamese TB patients, an association was also reported between Asian strains of M. tuberculosis causing infection and a polymorphism in the tolllike receptor 2 molecule in patients with TB meningitis [91] .
In summary, GWAS have identified a number of genes that appear to influence host susceptibility to infectious disease. The role of these genes needs further exploration in the context of their interactions with pathogen genes and environmental factors and a systematic approach, applying new '-omics' technology to both the host and pathogen genomes (and vector where applicable), will be required.
Key Points
Infectious diseases have exerted a major selective pressure on human evolution. Infectious diseases are common yet the genetics of susceptibility is relatively poorly understood. There are two genomes involved in susceptibility to infectious diseases. A number of genes in both the innate and adaptive immune systems have been identified as susceptibility/resistance genes or as disease modifier genes. Identification of pathways involved in immunity to common infections may facilitate the development of new treatments and vaccines.
